It should be mentioned that one ETP‐ALL patient first received venetoclax combined with chemotherapy regimen including low doses of cytarabine (LDAC), granulocyte colony‐stimulating factor (G‐CSF), and homoharringtonine (HAG), one ALAL patient also first received venetoclax combined with azacytidine as well as VP regimen, and both achieved complete remission (CR; Patients 15 and 18, Table 2). The gene discussed is CSF3; the disease is acute lymphoblastic leukemia.